Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01692236 · ClinicalTrials.gov registry record
Brain Imaging for HIV-Associated Thinking and Mood Disorders
A clinical trial, sponsored by National Institutes of Health Clinical Center (CC).
- Terminated
- Registry status
- 84
- Enrollment target
NCT01692236: Clinical Trial study, sponsored by National Institutes of Health Clinical Center (CC).
NCT01692236 is a clinical trial that was terminated before completion, run by National Institutes of Health Clinical Center (CC). The registered enrollment target is 84 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01692236 was terminated before completion, sponsored by National Institutes of Health Clinical Center (CC).
- TERMINATED
- Registry status
- 84 participants
- Enrollment target
Study Summary
Background: \- Human immunodeficiency virus (HIV) infection appears to cause problems with blood vessel function. These problems may add to some thinking and mood disorders found in people with HIV infection. Researchers want to evaluate HIV infected patients to see if blood vessel function contributes to thinking and mood disorders, such as early dementia and depression. To do so, they will compare study results between people with and people without HIV infection. Objectives: * To compare the thickness of blood vessel walls between people with and without HIV infection. * To study the relationship between blood vessel thickness and thinking and mood disorders. Eligibility: * Individuals between 25 and 55 years of age who have HIV infection. * Healthy individuals between 25 and 55 years of age. Design: * Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. * Participants will have imaging studies of the brain and major blood vessels in the head and neck. * Participants will also have neuropsychological testing. These tests will look at memory, learning and thinking ability, attention, and mood. * Participants will have the option of coming back for repeat blood tests every six months and repeat imaging studies and neuropsychological tests every year, over 1- 4 years period.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2012-09-13 |
| Est. Completion | 2018-04-04 |
Why NCT01692236 stopped before completion
NCT01692236 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 84 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT01692236 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01692236 about?
NCT01692236 is a clinical study titled "Brain Imaging for HIV-Associated Thinking and Mood Disorders". Background: \- Human immunodeficiency virus (HIV) infection appears to cause problems with blood vessel function. These problems may add to some thinking and mood disorders found in people with HIV infection. Researchers want to evaluate HIV infected patients to see if blood vessel function contrib...
What is the current status of trial NCT01692236?
This trial is currently terminated. The enrollment target is 84 participants. The study started on 2012-09-13. Estimated completion is 2018-04-04.
Who is sponsoring clinical trial NCT01692236?
This trial is sponsored by National Institutes of Health Clinical Center (CC), which has 338 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI